Kadimastem Ltd (KMSTF)
USD 0.64
(-90.0%)
USD 0.64
(-90.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.5 Million USD | 1.4% |
| 2022 | 3.45 Million USD | -10.2% |
| 2021 | 3.84 Million USD | -34.45% |
| 2020 | 5.87 Million USD | 5.0% |
| 2019 | 5.59 Million USD | 165.25% |
| 2018 | 2.1 Million ILS | -6.79% |
| 2017 | 2.26 Million ILS | -34.64% |
| 2016 | 3.46 Million ILS | -61.29% |
| 2015 | 8.94 Million ILS | -14.66% |
| 2014 | 10.47 Million ILS | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 2.52 Million USD | 0.0% |
| 2023 Q4 | 3.5 Million USD | 0.0% |
| 2023 FY | 3.5 Million USD | 1.4% |
| 2022 FY | 3.45 Million USD | -10.2% |
| 2022 Q2 | 3.93 Million ILS | 0.0% |
| 2022 Q4 | 3.45 Million USD | 0.0% |
| 2021 Q2 | 5.72 Million ILS | 0.0% |
| 2021 FY | 3.84 Million USD | -34.45% |
| 2021 Q4 | 3.84 Million ILS | 0.0% |
| 2020 FY | 5.87 Million USD | 5.0% |
| 2020 Q1 | 18.89 Million ILS | 237.85% |
| 2020 Q2 | 5.19 Million ILS | -72.48% |
| 2020 Q4 | 5.87 Million USD | 0.0% |
| 2019 FY | 5.59 Million USD | 165.25% |
| 2019 Q4 | 5.59 Million ILS | 0.0% |
| 2019 Q2 | 2.65 Million ILS | 0.0% |
| 2018 FY | 2.1 Million ILS | -6.79% |
| 2018 Q4 | 7.87 Million ILS | 0.0% |
| 2018 Q2 | 7.94 Million ILS | 0.0% |
| 2017 FY | 2.26 Million ILS | -34.64% |
| 2017 Q4 | 7.85 Million ILS | 0.0% |
| 2017 Q2 | 11.78 Million ILS | 0.0% |
| 2016 FY | 3.46 Million ILS | -61.29% |
| 2016 Q4 | 13.31 Million ILS | 0.0% |
| 2015 FY | 8.94 Million ILS | -14.66% |
| 2014 FY | 10.47 Million ILS | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -12676.098% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 62.974% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.164% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -333.345% |
| Rebus Holdings, Inc. | 5.24 Million USD | 33.139% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 94.061% |
| Qrons Inc. | 1.48 Million USD | -135.429% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -185.829% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.322% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -7741.567% |
| Skye Bioscience, Inc. | 14.07 Million USD | 75.094% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.425% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 63.422% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -731.388% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.996% |
| Intellipharmaceutics International Inc. | 12 Million USD | 70.814% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 8.998% |
| Mesoblast Limited | 188.44 Million USD | 98.14% |
| Marizyme, Inc. | 26.67 Million USD | 86.861% |
| Genus plc | 485 Million USD | 99.277% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 40.012% |
| Pharming Group N.V. | 244.07 Million USD | 98.564% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -74.36% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -39.285% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 7.767% |
| ContraFect Corporation | 32.53 Million USD | 89.226% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -76.897% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 8.433% |
| IMV Inc. | 37.93 Million USD | 90.76% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 70.243% |
| MultiCell Technologies, Inc. | 1617.67 USD | -216561.433% |
| ONE Bio Corp. | 27.49 Million USD | 87.253% |
| Accustem Sciences Inc. | 1.07 Million USD | -224.754% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.473% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -65.709% |
| Q BioMed Inc. | 8.13 Million USD | 56.905% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.774% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 31.892% |
| Biomind Labs Inc. | 1.49 Million USD | -133.874% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.048% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 61.239% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 80.955% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -144.436% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2366.566% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1642.709% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 39.001% |
| GB Sciences, Inc. | 5.41 Million USD | 35.305% |
| Alpha Cognition Inc. | 7.16 Million USD | 51.082% |
| HST Global, Inc. | 593.59 Thousand USD | -490.45% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -178.342% |
| Halberd Corporation | 728.71 Thousand USD | -380.963% |
| Enzolytics Inc. | 365.26 Million USD | 99.04% |
| Agentix Corp. | 2.51 Million USD | -39.605% |
| Resverlogix Corp. | 67.39 Million USD | 94.8% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -317.877% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.212% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -104.485% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 85.837% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 70.555% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 4.374% |
| AVAX Technologies, Inc. | 3.99 Million USD | 12.241% |
| Zenith Capital Corp. | 27.56 Thousand USD | -12613.073% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.736% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1368.598% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 6.144% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -414.79% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -29.253% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5136.694% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 93.027% |
| BioStem Technologies, Inc. | 15.9 Million USD | 77.963% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -654.223% |
| LadRx Corporation | 2.2 Million USD | -59.274% |
| Cell Source, Inc. | 15.8 Million USD | 77.827% |
| Regen BioPharma, Inc. | 5.45 Million USD | 35.78% |
| Regen BioPharma, Inc. | 5.45 Million USD | 35.78% |
| NovAccess Global Inc. | 7.86 Million USD | 55.413% |
| Affymax, Inc. | 8.87 Million USD | 60.491% |
| Itoco Inc. | 1.65 Million USD | -112.011% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -70.839% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 42.059% |
| Mobile Lads Corp. | 1.31 Million USD | -166.835% |
| CytoDyn Inc. | 127.89 Million USD | 97.26% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8285.05% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -123.756% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 68.268% |
| SYBLEU INC | 681.41 Thousand USD | -414.353% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 42.561% |
| International Stem Cell Corporation | 5.27 Million USD | 33.582% |
| Bioxytran, Inc. | 3.24 Million USD | -7.859% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -460.054% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 24.09% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.451% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 84.258% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -73.047% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 36.019% |
| Neutra Corp. | 973.52 Thousand USD | -260.017% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.92% |
| PureTech Health plc | 125.58 Million USD | 97.209% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 6.714% |
| IXICO plc | 1.9 Million USD | -84.438% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 82.927% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.608% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Cellectis S.A. | 249.36 Million USD | 98.595% |